LY6E: Lymphocyte Antigen 6 Family Member E
A GPI-anchored immune regulator and viral restriction factor
Gene Information Card
| Symbol | LY6E |
|---|---|
| Full Name | Lymphocyte Antigen 6 Family Member E |
| Gene Type | Protein coding |
| Chromosomal Location | 8q24.3 |
| NCBI Gene ID | 4061 ncbi.nlm.nih.gov/gene/4061 |
| Ensembl ID | ENSG00000160932 |
| UniProt ID | Q16553 |
| OMIM ID | 601384 |
| HGNC ID | 6729 |
| Aliases | RIG-E, SCA-2, TSA-1 |
Description
LY6E encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Ly6/uPAR family. It is involved in immune cell regulation, T cell activation, and modulation of viral entry. LY6E is highly expressed in hematopoietic tissues and is upregulated in response to interferons. It has been identified as a host factor that restricts infection by enveloped viruses, including SARS-CoV-2, influenza A, and HIV-1.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| COVID-19 | LY6E restricts SARS-CoV-2 entry by inhibiting membrane fusion | PMID: 32818467 |
| Influenza A | LY6E blocks influenza A virus entry at the fusion step | PMID: 28325809 |
| HIV-1 | LY6E inhibits HIV-1 infection by interfering with viral fusion | PMID: 28325809 |
| Breast cancer | Overexpression of LY6E correlates with poor prognosis and metastasis | PMID: 25609812 |
| Acute myeloid leukemia | LY6E is upregulated in AML and associated with leukemic stem cell markers | PMID: 21931115 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lung | 12.5 | Medium |
| Spleen | 45.3 | High |
| Bone marrow | 38.7 | High |
| Lymph node | 30.1 | High |
| Blood | 22.4 | Medium |
| Liver | 3.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| THP-1 (monocyte) | 28.6 | High expression; upregulated by IFN-gamma |
| Jurkat (T cell) | 35.2 | High expression; involved in T cell activation |
| HEK293 (embryonic kidney) | 5.1 | Low baseline expression |
| A549 (lung carcinoma) | 8.3 | Moderate expression; induced by type I IFN |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1A>G | Missense | <0.01% | Unknown functional effect |
| c.124C>T | Synonymous | <0.01% | No predicted effect |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in COSMIC or ClinVar.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • plasma membrane (GO:0005886) | • cell surface (GO:0009986) |
| • anchored component of plasma membrane (GO:0046658) | • immune response (GO:0006955) |
| • innate immune response (GO:0045087) | • virion attachment to host cell (GO:0019068) |
| • negative regulation of viral entry into host cell (GO:0046597) |
Pathways
• Interferon signaling (Reactome: R-HSA-913531)
• Antiviral mechanism by IFN-stimulated genes (Reactome: R-HSA-1169410)
• Innate immune system (Reactome: R-HSA-168249)
Protein Summary
LY6E is a small, GPI-anchored cell surface protein (131 amino acids) with a single LU domain. It is expressed on hematopoietic cells and upregulated by interferons. The protein localizes to the plasma membrane and endosomes, where it inhibits viral membrane fusion. In cancer, LY6E promotes cell migration and invasion, and its overexpression is linked to poor prognosis in breast cancer and leukemia.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| LY6E Knockout HEK293 Cell Line | EDJ-KQ5155 | Human | 4061 | Details Get a Quote |
| LY6E Knockout A-549 Cell Line | EDJ-KQ28129 | Human | 4061 | Details Get a Quote |
| LY6E Knockout HCT 116 Cell Line | EDJ-KQ28130 | Human | 4061 | Details Get a Quote |
| LY6E Knockout HeLa Cell Line | EDJ-KQ28131 | Human | 4061 | Details Get a Quote |
